Dental PlaquePhase 4NCT02884817
Essential Oil+ELA, Plaque and Gingivitis
A Phase 4 study testing Experimental: essential oils and ELA and Water in people with Dental Plaque and Gingivitis, run by University of Oslo at 1 site in Norway.
Trial summary
A commercially available mouth rinse with ethyl lauroyl arginate and essential oils claims to have enhanced antimicrobial properties as compared to the traditional essential oil products. Read more about this study
- Who is it for?
- Ages 20 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Dental Plaque, Gingivitis
- What is being tested?
- Experimental: essential oils and ELA and Water
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 59 participants
- Where
- 1 siteNorway
- Study dates
- Sep 2015to Oct 2015
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy subjects from both gender snon-smoking aged 20-55yr having at least three of the following teeth in maxillary right and left quadrant: the canine, 1st bicuspid, 2nd bicuspid, 1st molar, healthy gingiva and periodontium.
Who cannot join
- pregnancy lactation any chronic diseases clinical signs or symptoms of acute infection in the oral cavity any prescribed or non-prescription systemic or topical medication except oral contraceptives clinical parameters judged as unacceptable by the principle investigator use of systemic antibiotics the last 3 months prior to the start of the study history of alcohol or drug abuse participation in other clinical studies in the last 4weeks
Trial locations and contacts
1 site in 1 country.
Norway1 site
Department of Periodontology, Institute of Clinical Odontology, Dental Faculty, University of Oslo
Oslo, Oslo, 0455
About this study
Official title: The Plaque- and Gingivitis Inhibiting Capacity of a Commercially Available Mouthwash Containing Essential Oils and Ethyl Lauroyl Arginate: A Parallel, Split-mouth, Double Blind, Randomized, Placebo-controlled Clinical Study
A commercially available mouth rinse with ethyl lauroyl arginate and essential oils claims to have enhanced antimicrobial properties as compared to the traditional essential oil products. The aim of the present study was to compare the plaque and gingivitis inhibiting effect of the commercial product containing essential oils with ethyl lauroyl arginate with one placebo and one negative control in a modified experimental gingivitis model. In three groups of healthy volunteers, experimental gingivitis was induced and monitored over 21 days, simultaneously treated with the commercial test solution, 21.6% hydro-alcohol solution and sterile water respectively. The maxillary right quadrant of each individual received mouthwash only, whereas the maxillary left quadrant was subject to both rinsing and mechanical oral hygiene. Compliance and side effects were monitored at day 7, 14, and 21. Plaque and gingivitis scores were obtained at baseline and at day 21.
Read the detailed description
Mouthrinses containing essential oils in 21% - 26% alcohol are claimed to be potent inhibitors of plaque formation, although a recently published study suggests otherwise.
Recently, a new product in this series of mouthwashes was introduced in which an additional antimicrobial agent, Ethyl Lauroyl Arginate, derived from lauric acid and arginine had been added to the standard essential oils and alcohol. Ethyl Lauroyl Arginate acts as a cationic surfactant and has a wide spectrum of activities against Gram positive and - negative bacteria, yeasts and fungi and acts by modifying the permeability of membranes. Ethyl Lauroyl Arginate is used as a multi-functional component in formulations of cosmetic and toiletry products, claiming to act as an anti-static agent and a surfactant with antimicrobial properties. The Scientific Committee on Consumer Safety, has evaluated the safety and use of the ingredient and considered Ethyl Lauroyl Arginate as a safe product when used up to a maximum concentration of 0,15 % in oral dental products. The manufacturer of Essential Oils with Ethyl Lauroyl Arginate claims that Ethyl Lauroyl Arginate prevents the formation of biofilms, and represents a totally new way to combat biofilm-diseases like caries, gingivitis and periodontitis. Moreover, the manufacturer announces that the product reduces plaque colonization of dental surfaces with up to 42.6% and bleeding with up to 50.9% in 4 weeks.
Few or no clinical studies of this new mouthwash have been published, although some informational material is cited in marketing pamphlets.
Thus, the Aim of the present study was to test the clinical plaque- and gingivitis inhibiting capacity of Essential Oils with Ethyl Lauroyl Arginate, with or without mechanical oral hygiene, using a modified experimental gingivitis model, with 21.6 % hydroalcoholic and sterile water as controls.
The HYPOTHESIS was that the test solution was equally effective in preventing dental plaque as the placebo solution in the Experimental gingivitis model.
The present study was designed as a parallel, split-mouth, double masked, randomized, placebo-controlled clinical study. The experimental gingivitis model, with the modifications by Preus et al. was used to induce gingival inflammation under supervised conditions throughout the study. The study was approved by the Regional Committee for Medical Research Ethics, South East Norway, in 2015 and follows the Consort 2010 guidelines.
The study population comprised seventy-four dental, medical, and dental hygienist students, as well as a few clinical teachers, who volunteered to participate in the project. An information meeting was arranged for the volunteers prior to the start of the study, through which the participants received information about oral rinsing products in general and Ethyl Lauroyl Arginate/Essential Oils with Ethyl Lauroyl Arginate products as well as information on the study ahead, in particular. Fifteen subjects withdrew for personal reasons at this time, mostly because they became aware that they could not brush their teeth in the 1st quadrant for 21 days, resulting in fifty-nine participants signing the informed consent form. Mean age was 25 +/- 3.2yr and 78% were females. The study period was 21days, not comprising any special academic, religious or ethnic feasts or events that could jeopardize the collective behavior of the study population. All information, administration and data collection was performed at the Department of Periodontology, Institute of Clinical Odontology, Faculty of Dentistry, University of Oslo, Norway.
Inclusion criteria \& Exclusion criteria are listed under "inclusion and Exclusion criteria" below.
The test solution was the commercially available mouthwash product Essential Oils with Ethyl Lauroyl Arginate that contains essential oils and Ethyl Lauroyl Arginate in 21.6% alcohol . The first control was the true placebo solution; a hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%. The second control solution, plain sterilized water, was used as the negative control because this has been used as control in most studies testing the effect of Ethyl Lauroyl Arginate products. Both control solutions were enriched with 0.2% Fluorid in order to prevent development of early carious lesions during the course of the study. The test solution was not fluoridated since it could change the activity of the active ingredients. The three solutions were filled in identical, labeled (1,2 or 3) bottles.
Randomization was carried out using a computer generated random allocation table assigning the participants to the three study groups with 20 test subjects in each of groups 2 and 3. Group 1 contained 19 participants. They were all carefully instructed to rinse for 30 seconds twice a day with the content of their designated mouthwash. 30 seconds was recommended by the manufacturer for the test solution and was therefore recommended for the controls as well. The statistician performed the randomization whereas the project leader distributed the rinsing solutions and instructions after a list generated as described.
Setting the baseline dental plaque score to zero was done by giving all participants a professional tooth cleaning with rubber cup, pumice paste and dental floss prior to the start of the study on the first day of the study period. Passing baseline, the participants were given their test solution and subsequently instructed to rinse, supervised by the project leader (there and then), as described above with the allocated test solution. This was done since Ethyl Lauroyl Arginate is claimed to be an inhibitor of biofilm formation, and should therefore be applied immediately following the removal of the biofilm. Individual plastic tooth guards had been produced to fit the teeth in the upper right quadrant of each participant prior to baseline. Together with this individual tooth guard, the participants were given identical prophylaxis packs containing a medium texture tooth brush, inter-dental floss and dentifrice. They were instructed to substitute their daily oral hygiene remedies with the ones given to them, and attach the tooth guard to the toothbrush, with a provided rubber string, initially and after use so that the tooth guard always was remembered when using the brush.
The participants were instructed to insert the tooth guard in Quadrant 1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30 seconds with water before removing the tooth guard. And then rinse again for 30 seconds with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the solution they randomly had been assigned. This oral hygiene routine was repeated for 21 days. The study design and stringency of logistics ensured that the study participants served as their own controls, as one quadrant was exposed to chemical rinsing only (quadrant 1) and the upper left quadrant (Quadrant 2) received traditional tooth brushing and inter-dental cleaning in addition to the chemical rinsing. Following the last scoring at day 21, the participants received professional tooth cleaning after scoring and before ending the study.
A team of four people were trained in the procedure of informing participants, receiving the test persons for evaluation, questionnaire and clinically monitoring them at all visits. The principal investigator and project managers managed all contact with the participants outside the scoring room. In between appointments the project team kept in touch with the test persons by text messaging and e-mail. The success of this service was evident by zero no-shows at the clinic, as was the case also in the previous studies with this design.
Preceding every examination, the project managers interviewed each participant about compliance and received verbal complaints and descriptions of subjective side-effects. Before entering the scoring room ordered the participants to refrain from any conversation with the scoring scientists inside. The recorders had been instructed likewise.
In the scoring room, two researchers obtained the clinical data. At days 7 and 14 the clinical recordings was based on clinical appearance of adverse effects of the respective solutions. Moreover, these visits were also thought to be important in following the protocol for all participants. At day 21 the plaque index (primary endpoint) and secondary endpoint gingival index (secondary endpoint) were recorded on the mesial, buccal, distal and palatal aspects of teeth 16, 15, 14, 13 and 23, 24, 25, 26. Adverse events like discoloration observed during the clinical examination (yes/no) and clinically visible oral mucosal reactions were registered. In addition, Quigley and Hine plaque index; the Turesky modification, was registered following the above scoring method and dying the Quadrant 1 and Quadrant 2. All clinical registrations were performed by the same experienced periodontist, leaving her colleague to register recordings on especially designed charts. The clinical crew was kept blind to the group allocation of the participants at all times, as the only one that had access to the code-book was the statistician who did not participate in the clinical events.
Statistical analyses The total number of participants was 59, with 19 subjects in group 1, and 20 subjects in group 2 and 3 (using a two-sided t-test with 5% significance level); the test power to detect a true mean difference in Gingival - and Plaque index was above 80%. This power analysis was based on the variable delta plaque, meaning the difference in mean plaque between 1st and 2nd quadrant (test minus control quadrant). When comparing mean variable delta plaque in two groups, a two-sided independent samples t-test was used, with 5% significance level. In the present study sample size was 15 patients in each group. Average standard deviation of DP in the three groups was 0.40. It may be shown that the test power to detect a mean difference of at least 0.40 in the present study when comparing two groups was 78%. As 80% test power is generally considered acceptable in clinical studies and the difference in mean variable Delta Plaque between group 3 and group 1 was 0.49, the above calculation suggests that our study has acceptable test power.
Interval estimates of primary efficacy variables were constructed using 95% as the level of confidence and an overall significance level of 5% was used in the statistical tests. All tests were performed two-sided. The statistical analyses were conducted using the software of Statistical Package for the Social Sciences (SPSS) for Windows, Version 16.0. The difference between groups at day 7, 14 and 21 were tested using an independent samples t-test.
One-way Anova analysis was not used when analyzing the outcome variables, because we considered it most interesting to compare the Alcohol - (group 2) and the Essential Oils with Ethyl Lauroyl Arginate - (group 3) with the reference water group (group 1). The distributions of the outcome variables were checked in hindsight, and found to be sufficiently close to the normal distribution to allow for the use of a t-test.
- Conditions
- Dental Plaque, Gingivitis
- Being tested
- Experimental: essential oils and ELA, Placebo, Water
- Medical subject headings
- Dental Plaque, Gingivitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Experimental: essential oils and ELADrug
Also called Listerine Professional Gum Therapy®, Johnson & Johnson,USA
The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
PlaceboOther
Also called 21.6% hydroalcoholic
The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
WaterOther
Also called Sham Comparator
The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
| Study group | Role | What they receive |
|---|---|---|
| Listerine prof.gum.ther | Experimental | The test solution was the commercially available mouthwash product EOELA that contains essential oils and ELA in 21.6% alcohol (Listerine Professional Gum Therapy®, Johnson \& Johnson,USA).
Intervention; Rinsing 30 sec with test solution twice daily for 21 days Receives: Drug: Experimental: essential oils and ELA |
| 21.6% hydroalcoholic | Placebo comparator | a hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%.
Intervention: Rinsing 30 sec with placebo comparator twice daily for 21 days Receives: Other: Placebo |
| Plain sterile water | Sham comparator | Plain sterile water.
Intervention: Rinsing 30 sec with sham comparator twice daily for 21 days Receives: Other: Water |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plaque index (Silness & Loe 1964)
0= No plaque
- A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may be seen in situ only after application of disclosing solution or by using the probe on the tooth surface.
- Moderate accumulation of soft deposit s within the gingival pocket, or the tooth and gingival margin which can be seen with the naked eye.
- Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin.
Measured: 21 days
Secondary outcomes (1)
The gingival index (GI) (Løe & Silness 1963)
0 No inflammation.
- Mild inflammation, slight change in color, slight edema, no bleeding on probing.
- Moderate inflammation, moderate glazing, redness, bleeding on probing.
- Severe inflammation, marked redness and hypertrophy, ulceration, tendency to spontaneous bleeding.
Measured: 21 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2016 (estimated)
- Study startSep 2015
- Primary completionOct 2015
- Study completionOct 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (25)Papers the sponsor has linked to this study.
- Other trials for Dental PlaqueStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 59 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oslo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hans Ragnar Preus, University of Oslo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02884817
- Sponsor's protocol ID
- REK2015/417
- Status last verified
- Aug 2016
- First submitted
- 22 Aug 2016
- Last updated
- 31 Aug 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Yes: Via scientific journals
Publications
McCullough MJ, Farah CS. The role of alcohol in oral carcinogenesis with particular reference to alcohol-containing mouthwashes. Aust Dent J. 2008 Dec;53(4):302-5. doi: 10.1111/j.1834-7819.2008.00070.x.
PubMed 19133944Van Leeuwen MP, Slot DE, Van der Weijden GA. Essential oils compared to chlorhexidine with respect to plaque and parameters of gingival inflammation: a systematic review. J Periodontol. 2011 Feb;82(2):174-94. doi: 10.1902/jop.2010.100266. Epub 2010 Nov 2.
PubMed 21043801Preus HR, Koldsland OC, Aass AM, Sandvik L, Hansen BF. The plaque- and gingivitis-inhibiting capacity of a commercially available essential oil product. A parallel, split-mouth, single blind, randomized, placebo-controlled clinical study. Acta Odontol Scand. 2013 Nov;71(6):1613-9. doi: 10.3109/00016357.2013.782506. Epub 2013 May 3.
PubMed 23638764Hawkins DR, Rocabayera X, Ruckman S, Segret R, Shaw D. Metabolism and pharmacokinetics of ethyl N(alpha)-lauroyl-L-arginate hydrochloride in human volunteers. Food Chem Toxicol. 2009 Nov;47(11):2711-5. doi: 10.1016/j.fct.2009.07.028. Epub 2009 Aug 3.
PubMed 19651183Gallob JT, Lynch M, Charles C, Ricci-Nittel D, Mordas C, Gambogi R, Revankar R, Mutti B, Labella R. A randomized trial of ethyl lauroyl arginate-containing mouthrinse in the control of gingivitis. J Clin Periodontol. 2015 Aug;42(8):740-747. doi: 10.1111/jcpe.12428. Epub 2015 Aug 15.
PubMed 26087864LOE H, THEILADE E, JENSEN SB. EXPERIMENTAL GINGIVITIS IN MAN. J Periodontol (1930). 1965 May-Jun;36:177-87. doi: 10.1902/jop.1965.36.3.177. No abstract available.
PubMed 14296927Preus HR, Aass AM, Hansen BF, Moe B, Gjermo P. A randomized, single-blind, parallel-group clinical study to evaluate the effect of soluble beta-1,3/1,6-glucan on experimental gingivitis in man. J Clin Periodontol. 2008 Mar;35(3):236-41. doi: 10.1111/j.1600-051X.2007.01183.x.
PubMed 18269662Altman DG. Clinical Trials. Practical statistics for medical research. London:Chapman & Hall/CRC, 1991;456.
QUEIROZ DR, MORDAS CJ, MARTINEZ MD, SHANG H, GAMBOGI RJ. Examination of Ethyl-Lauroyl-Arginate-HCl (LAE) Deposition on a Model Enamel Surface. IADR Abstract and Programme 2015; Abstr 0559, Boston March 12th, 2015
http://www.google.com/patents/US20040258632 *
https://www.foodstandards.gov.au/code/applications/documents/AR_A1015.pdf *
http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_017.pdf *
http://www.lamirsa.com/mirenat/pdf/03-PCT.pdf
http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_138.pdf
http://www.nature.com/bdj/journal/v218/n6/full/sj.bdj.2015.234.html
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Plaque- and Gingivitis Inhibiting Capacity of a Commercially Available Mouthwash Containing Essential Oils and Ethyl Lauroyl Arginate: A Parallel, Split-mouth, Double Blind, Randomized, Placebo-controlled Clinical Study
- ClinicalTrials.gov ID
- NCT02884817
- Acronym / sponsor ID
- REK2015/417
- Conditions
- Dental Plaque, Gingivitis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 59 participants (actual)
- Lead sponsor
- University of OsloUniversity, hospital or other
- Study start
- Sep 2015
- Primary completion
- Oct 2015 (actual)
- Study completion
- Oct 2015 (actual)
- First posted
- 31 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A commercially available mouth rinse with ethyl lauroyl arginate and essential oils claims to have enhanced antimicrobial properties as compared to the traditional essential oil products. The aim of the present study was to compare the plaque and gingivitis inhibiting effect of the commercial product containing essential oils with ethyl lauroyl arginate with one placebo and one negative control in a modified experimental gingivitis model. In three groups of healthy volunteers, experimental gingivitis was induced and monitored over 21 days, simultaneously treated with the commercial test solution, 21.6% hydro-alcohol solution and sterile water respectively. The maxillary right quadrant of each individual received mouthwash only, whereas the maxillary left quadrant was subject to both rinsing and mechanical oral hygiene. Compliance and side effects were monitored at day 7, 14, and 21. Plaque and gingivitis scores were obtained at baseline and at day 21.
Detailed description
Mouthrinses containing essential oils in 21% - 26% alcohol are claimed to be potent inhibitors of plaque formation, although a recently published study suggests otherwise.
Recently, a new product in this series of mouthwashes was introduced in which an additional antimicrobial agent, Ethyl Lauroyl Arginate, derived from lauric acid and arginine had been added to the standard essential oils and alcohol. Ethyl Lauroyl Arginate acts as a cationic surfactant and has a wide spectrum of activities against Gram positive and - negative bacteria, yeasts and fungi and acts by modifying the permeability of membranes. Ethyl Lauroyl Arginate is used as a multi-functional component in formulations of cosmetic and toiletry products, claiming to act as an anti-static agent and a surfactant with antimicrobial properties. The Scientific Committee on Consumer Safety, has evaluated the safety and use of the ingredient and considered Ethyl Lauroyl Arginate as a safe product when used up to a maximum concentration of 0,15 % in oral dental products. The manufacturer of Essential Oils with Ethyl Lauroyl Arginate claims that Ethyl Lauroyl Arginate prevents the formation of biofilms, and represents a totally new way to combat biofilm-diseases like caries, gingivitis and periodontitis. Moreover, the manufacturer announces that the product reduces plaque colonization of dental surfaces with up to 42.6% and bleeding with up to 50.9% in 4 weeks.
Few or no clinical studies of this new mouthwash have been published, although some informational material is cited in marketing pamphlets.
Thus, the Aim of the present study was to test the clinical plaque- and gingivitis inhibiting capacity of Essential Oils with Ethyl Lauroyl Arginate, with or without mechanical oral hygiene, using a modified experimental gingivitis model, with 21.6 % hydroalcoholic and sterile water as controls.
The HYPOTHESIS was that the test solution was equally effective in preventing dental plaque as the placebo solution in the Experimental gingivitis model.
The present study was designed as a parallel, split-mouth, double masked, randomized, placebo-controlled clinical study. The experimental gingivitis model, with the modifications by Preus et al. was used to induce gingival inflammation under supervised conditions throughout the study. The study was approved by the Regional Committee for Medical Research Ethics, South East Norway, in 2015 and follows the Consort 2010 guidelines.
The study population comprised seventy-four dental, medical, and dental hygienist students, as well as a few clinical teachers, who volunteered to participate in the project. An information meeting was arranged for the volunteers prior to the start of the study, through which the participants received information about oral rinsing products in general and Ethyl Lauroyl Arginate/Essential Oils with Ethyl Lauroyl Arginate products as well as information on the study ahead, in particular. Fifteen subjects withdrew for personal reasons at this time, mostly because they became aware that they could not brush their teeth in the 1st quadrant for 21 days, resulting in fifty-nine participants signing the informed consent form. Mean age was 25 +/- 3.2yr and 78% were females. The study period was 21days, not comprising any special academic, religious or ethnic feasts or events that could jeopardize the collective behavior of the study population. All information, administration and data collection was performed at the Department of Periodontology, Institute of Clinical Odontology, Faculty of Dentistry, University of Oslo, Norway.
Inclusion criteria \& Exclusion criteria are listed under "inclusion and Exclusion criteria" below.
The test solution was the commercially available mouthwash product Essential Oils with Ethyl Lauroyl Arginate that contains essential oils and Ethyl Lauroyl Arginate in 21.6% alcohol . The first control was the true placebo solution; a hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%. The second control solution, plain sterilized water, was used as the negative control because this has been used as control in most studies testing the effect of Ethyl Lauroyl Arginate products. Both control solutions were enriched with 0.2% Fluorid in order to prevent development of early carious lesions during the course of the study. The test solution was not fluoridated since it could change the activity of the active ingredients. The three solutions were filled in identical, labeled (1,2 or 3) bottles.
Randomization was carried out using a computer generated random allocation table assigning the participants to the three study groups with 20 test subjects in each of groups 2 and 3. Group 1 contained 19 participants. They were all carefully instructed to rinse for 30 seconds twice a day with the content of their designated mouthwash. 30 seconds was recommended by the manufacturer for the test solution and was therefore recommended for the controls as well. The statistician performed the randomization whereas the project leader distributed the rinsing solutions and instructions after a list generated as described.
Setting the baseline dental plaque score to zero was done by giving all participants a professional tooth cleaning with rubber cup, pumice paste and dental floss prior to the start of the study on the first day of the study period. Passing baseline, the participants were given their test solution and subsequently instructed to rinse, supervised by the project leader (there and then), as described above with the allocated test solution. This was done since Ethyl Lauroyl Arginate is claimed to be an inhibitor of biofilm formation, and should therefore be applied immediately following the removal of the biofilm. Individual plastic tooth guards had been produced to fit the teeth in the upper right quadrant of each participant prior to baseline. Together with this individual tooth guard, the participants were given identical prophylaxis packs containing a medium texture tooth brush, inter-dental floss and dentifrice. They were instructed to substitute their daily oral hygiene remedies with the ones given to them, and attach the tooth guard to the toothbrush, with a provided rubber string, initially and after use so that the tooth guard always was remembered when using the brush.
The participants were instructed to insert the tooth guard in Quadrant 1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30 seconds with water before removing the tooth guard. And then rinse again for 30 seconds with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the solution they randomly had been assigned. This oral hygiene routine was repeated for 21 days. The study design and stringency of logistics ensured that the study participants served as their own controls, as one quadrant was exposed to chemical rinsing only (quadrant 1) and the upper left quadrant (Quadrant 2) received traditional tooth brushing and inter-dental cleaning in addition to the chemical rinsing. Following the last scoring at day 21, the participants received professional tooth cleaning after scoring and before ending the study.
A team of four people were trained in the procedure of informing participants, receiving the test persons for evaluation, questionnaire and clinically monitoring them at all visits. The principal investigator and project managers managed all contact with the participants outside the scoring room. In between appointments the project team kept in touch with the test persons by text messaging and e-mail. The success of this service was evident by zero no-shows at the clinic, as was the case also in the previous studies with this design.
Preceding every examination, the project managers interviewed each participant about compliance and received verbal complaints and descriptions of subjective side-effects. Before entering the scoring room ordered the participants to refrain from any conversation with the scoring scientists inside. The recorders had been instructed likewise.
In the scoring room, two researchers obtained the clinical data. At days 7 and 14 the clinical recordings was based on clinical appearance of adverse effects of the respective solutions. Moreover, these visits were also thought to be important in following the protocol for all participants. At day 21 the plaque index (primary endpoint) and secondary endpoint gingival index (secondary endpoint) were recorded on the mesial, buccal, distal and palatal aspects of teeth 16, 15, 14, 13 and 23, 24, 25, 26. Adverse events like discoloration observed during the clinical examination (yes/no) and clinically visible oral mucosal reactions were registered. In addition, Quigley and Hine plaque index; the Turesky modification, was registered following the above scoring method and dying the Quadrant 1 and Quadrant 2. All clinical registrations were performed by the same experienced periodontist, leaving her colleague to register recordings on especially designed charts. The clinical crew was kept blind to the group allocation of the participants at all times, as the only one that had access to the code-book was the statistician who did not participate in the clinical events.
Statistical analyses The total number of participants was 59, with 19 subjects in group 1, and 20 subjects in group 2 and 3 (using a two-sided t-test with 5% significance level); the test power to detect a true mean difference in Gingival - and Plaque index was above 80%. This power analysis was based on the variable delta plaque, meaning the difference in mean plaque between 1st and 2nd quadrant (test minus control quadrant). When comparing mean variable delta plaque in two groups, a two-sided independent samples t-test was used, with 5% significance level. In the present study sample size was 15 patients in each group. Average standard deviation of DP in the three groups was 0.40. It may be shown that the test power to detect a mean difference of at least 0.40 in the present study when comparing two groups was 78%. As 80% test power is generally considered acceptable in clinical studies and the difference in mean variable Delta Plaque between group 3 and group 1 was 0.49, the above calculation suggests that our study has acceptable test power.
Interval estimates of primary efficacy variables were constructed using 95% as the level of confidence and an overall significance level of 5% was used in the statistical tests. All tests were performed two-sided. The statistical analyses were conducted using the software of Statistical Package for the Social Sciences (SPSS) for Windows, Version 16.0. The difference between groups at day 7, 14 and 21 were tested using an independent samples t-test.
One-way Anova analysis was not used when analyzing the outcome variables, because we considered it most interesting to compare the Alcohol - (group 2) and the Essential Oils with Ethyl Lauroyl Arginate - (group 3) with the reference water group (group 1). The distributions of the outcome variables were checked in hindsight, and found to be sufficiently close to the normal distribution to allow for the use of a t-test.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Listerine prof.gum.ther | Experimental | Drug: Experimental: essential oils and ELAThe test solution was the commercially available mouthwash product EOELA that contains essential oils and ELA in 21.6% alcohol (Listerine Professional Gum Therapy®, Johnson \& Johnson,USA). Intervention; Rinsing 30 sec with test solution twice daily for 21 days |
| 21.6% hydroalcoholic | Placebo comparator | Other: Placeboa hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%. Intervention: Rinsing 30 sec with placebo comparator twice daily for 21 days |
| Plain sterile water | Sham comparator | Other: WaterPlain sterile water. Intervention: Rinsing 30 sec with sham comparator twice daily for 21 days |
Who may qualify
- Ages
- 20 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- healthy subjects from both gender snon-smoking aged 20-55yr having at least three of the following teeth in maxillary right and left quadrant: the canine, 1st bicuspid, 2nd bicuspid, 1st molar, healthy gingiva and periodontium.
Key exclusion criteria (1 listed)
- pregnancy lactation any chronic diseases clinical signs or symptoms of acute infection in the oral cavity any prescribed or non-prescription systemic or topical medication except oral contraceptives clinical parameters judged as unacceptable by the principle investigator use of systemic antibiotics the last 3 months prior to the start of the study history of alcohol or drug abuse participation in other clinical studies in the last 4weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Experimental: essential oils and ELAAlso: Listerine Professional Gum Therapy®, Johnson & Johnson,USAThe participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d. | Drug | Listerine prof.gum.ther |
| PlaceboAlso: 21.6% hydroalcoholicThe participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d. | Other | 21.6% hydroalcoholic |
| WaterAlso: Sham ComparatorThe participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d. | Other | Plain sterile water |
Primary outcome
Plaque index (Silness & Loe 1964)
Time frame: 21 days
0= No plaque 1. A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may be seen in situ only after application of disclosing solution or by using the probe on the tooth surface. 2. Moderate accumulation of soft deposit s within the gingival pocket, or the tooth and gingival margin which can be seen with the naked eye. 3. Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin.
1 secondary outcome
The gingival index (GI) (Løe & Silness 1963)
Time frame: 21 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2016.
- Background: PubMed 19133944McCullough MJ, Farah CS. The role of alcohol in oral carcinogenesis with particular reference to alcohol-containing mouthwashes. Aust Dent J. 2008 Dec;53(4):302-5. doi: 10.1111/j.1834-7819.2008.00070.x.
- Background: PubMed 21043801Van Leeuwen MP, Slot DE, Van der Weijden GA. Essential oils compared to chlorhexidine with respect to plaque and parameters of gingival inflammation: a systematic review. J Periodontol. 2011 Feb;82(2):174-94. doi: 10.1902/jop.2010.100266. Epub 2010 Nov 2.
- Background: PubMed 23638764Preus HR, Koldsland OC, Aass AM, Sandvik L, Hansen BF. The plaque- and gingivitis-inhibiting capacity of a commercially available essential oil product. A parallel, split-mouth, single blind, randomized, placebo-controlled clinical study. Acta Odontol Scand. 2013 Nov;71(6):1613-9. doi: 10.3109/00016357.2013.782506. Epub 2013 May 3.
- Background: PubMed 19651183Hawkins DR, Rocabayera X, Ruckman S, Segret R, Shaw D. Metabolism and pharmacokinetics of ethyl N(alpha)-lauroyl-L-arginate hydrochloride in human volunteers. Food Chem Toxicol. 2009 Nov;47(11):2711-5. doi: 10.1016/j.fct.2009.07.028. Epub 2009 Aug 3.
- Background: PubMed 26087864Gallob JT, Lynch M, Charles C, Ricci-Nittel D, Mordas C, Gambogi R, Revankar R, Mutti B, Labella R. A randomized trial of ethyl lauroyl arginate-containing mouthrinse in the control of gingivitis. J Clin Periodontol. 2015 Aug;42(8):740-747. doi: 10.1111/jcpe.12428. Epub 2015 Aug 15.
- Background: PubMed 14296927LOE H, THEILADE E, JENSEN SB. EXPERIMENTAL GINGIVITIS IN MAN. J Periodontol (1930). 1965 May-Jun;36:177-87. doi: 10.1902/jop.1965.36.3.177. No abstract available.
- Background: PubMed 18269662Preus HR, Aass AM, Hansen BF, Moe B, Gjermo P. A randomized, single-blind, parallel-group clinical study to evaluate the effect of soluble beta-1,3/1,6-glucan on experimental gingivitis in man. J Clin Periodontol. 2008 Mar;35(3):236-41. doi: 10.1111/j.1600-051X.2007.01183.x.
- BackgroundAltman DG. Clinical Trials. Practical statistics for medical research. London:Chapman & Hall/CRC, 1991;456.
- BackgroundQUEIROZ DR, MORDAS CJ, MARTINEZ MD, SHANG H, GAMBOGI RJ. Examination of Ethyl-Lauroyl-Arginate-HCl (LAE) Deposition on a Model Enamel Surface. IADR Abstract and Programme 2015; Abstr 0559, Boston March 12th, 2015
- Backgroundhttp://www.google.com/patents/US20040258632 *
- Backgroundhttps://www.foodstandards.gov.au/code/applications/documents/AR_A1015.pdf *
- Backgroundhttp://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_017.pdf *
- Individual participant dataSharing planned: Yes. Via scientific journals
Related trials for Dental Plaque
Not yet recruiting
Effect of Xylitol- Versus Erythritol-Sweetened Mints on Plaque ATP-Bioluminescence Readings
Dental Caries, Dental Plaque
Not yet recruitingObservational study
Plaque and Bleeding on Probing Around Implants Supporting Fixed Full-Arch Dental Prostheses
Peri-Implant Health
Not yet recruiting
Effectiveness of Oil Pulling Using Oils in Comparison With Mouthwash for Gingivitis
Gingivitis
Not yet recruiting
Individualized Management of Plaque-Related Gingival Inflammation in Routine Dental Practice
Plaque-Induced Gingivitis
Recruiting
The Study to Evaluate the Plaque Control and Anti-Gingivitis Efficacy of a Toothpaste in Chinese Population
Dental Plaque, Gingivitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Experimental: essential oils and ELA and Water in people with Dental Plaque and Gingivitis, run by University of Oslo at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plaque index (Silness & Loe 1964) (time frame: 21 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02884817, which also lists 25 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2016.